JP2015515462A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515462A5 JP2015515462A5 JP2015501731A JP2015501731A JP2015515462A5 JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5 JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5
- Authority
- JP
- Japan
- Prior art keywords
- blood
- pegylated
- composition
- subject
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004506 Blood Proteins Human genes 0.000 claims 12
- 108010017384 Blood Proteins Proteins 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 210000004369 Blood Anatomy 0.000 claims 9
- 239000008280 blood Substances 0.000 claims 9
- 102100001249 ALB Human genes 0.000 claims 8
- 101710027066 ALB Proteins 0.000 claims 8
- 229940050528 albumin Drugs 0.000 claims 8
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 208000007056 Sickle Cell Anemia Diseases 0.000 claims 3
- 230000003078 antioxidant Effects 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 210000003743 Erythrocytes Anatomy 0.000 claims 2
- 210000003324 RBC Anatomy 0.000 claims 2
- 239000012503 blood component Substances 0.000 claims 2
- 239000003914 blood derivative Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-Hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 1
- 206010018987 Haemorrhage Diseases 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 230000000111 anti-oxidant Effects 0.000 claims 1
- 230000000740 bleeding Effects 0.000 claims 1
- 231100000319 bleeding Toxicity 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000002086 nanomaterial Substances 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000001590 oxidative Effects 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 1
Claims (14)
- 対象への輸血の有効性を向上させる方法であって、PEG化アルブミンを含む組成物、PEG化かつポリニトロキシル化アルブミンを含む組成物又は抗酸化物質に共有結合しているPEG化アルブミンを含む組成物を前記対象に投与することを含み、前記組成物が、前記対象への輸血の前、最中、又は後に、該対象に投与される、方法。
- 鎌状赤血球症を治療するために輸血を既に受けた、受けている、又はこれから受ける対象における鎌状赤血球症を治療する方法であって、PEG化血液タンパク質を含む組成物又はPEG化血液タンパク質抗酸化物質接合体を含む組成物を前記対象に投与することを含み、前記PEG化血液タンパク質又はPEG化血液タンパク質抗酸化物質接合体が、前記対象への輸血の前、最中、又は後に、該対象に投与される、方法。
- 後の輸血に向けた、赤血球含有組成物、血液、又は血液誘導体の貯蔵に起因又は関連する1以上の損傷を低減する方法であって、前記赤血球含有組成物、血液、又は血液誘導体と、貯蔵に起因又は関連する1以上の損傷を低減するのに有効な量の、接合する抗酸化物質を有するか又は有さないEAF PEG化血液タンパク質及び/又は活性酸素種ナノ物質とを混合することを含む、方法。
- 前記PEG化血液タンパク質が伸長アーム促進性(EAF)PEG化血液タンパク質である、請求項1又は2に記載の方法。
- 前記組成物が4%ヘキサPEG化アルブミンを含む、請求項1又は2に記載の方法。
- 輸血が血液又は血液成分を含み、該血液又は血液成分が輸血の2週間前より先に供血者から得られたものである、請求項1、2又は3に記載の方法。
- 前記血液タンパク質がヘモグロビンである、請求項2〜6のいずれか一項に記載の方法。
- 前記血液タンパク質がアルブミンである、請求項2〜6のいずれか一項に記載の方法。
- 前記対象が、(i)出血を経験している;(ii)手術を受けている;(iii)過去30日の間に手術を受けた経験がある;(iv)出血性ショックの影響を受けている;(v)過去48時間以内に血液量の15%を超える量を失った経験がある;又は(vi)鎌状赤血球症を有している、請求項1又は2に記載の方法。
- 前記対象が輸血の前に血液希釈状態にある、請求項1又は2に記載の方法。
- 前記投与される組成物が1%〜10%のEAF PEG化血液タンパク質を含む、請求項2〜10のいずれか一項に記載の方法。
- 前記PEG化血液タンパク質を含む組成物のPEGが5000mwのPEGである、請求項1〜11のいずれか一項に記載の方法。
- 前記EAF PEG化血液タンパク質抗酸化物質接合体がEAF P5K6アルブミンテンポール12又は(EAF P5K6アルブミンテンポール12)nであり、ここで、nが1〜40の正の整数である、請求項3に記載の方法。
- 前記(EAF P5K6アルブミンテンポール12)nが使用され、ここで、nが4〜40の正の整数である、請求項13に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261613105P | 2012-03-20 | 2012-03-20 | |
US61/613,105 | 2012-03-20 | ||
PCT/US2013/030355 WO2013142135A1 (en) | 2012-03-20 | 2013-03-12 | Method of enhancing efficacy of blood transfusions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015515462A JP2015515462A (ja) | 2015-05-28 |
JP2015515462A5 true JP2015515462A5 (ja) | 2016-04-21 |
Family
ID=49223191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015501731A Pending JP2015515462A (ja) | 2012-03-20 | 2013-03-12 | 輸血の有効性を高める方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US8859499B2 (ja) |
EP (1) | EP2827887A4 (ja) |
JP (1) | JP2015515462A (ja) |
BR (1) | BR112014023200A2 (ja) |
CL (1) | CL2014002464A1 (ja) |
HK (1) | HK1204267A1 (ja) |
IN (1) | IN2014MN02089A (ja) |
MX (1) | MX2014011186A (ja) |
WO (1) | WO2013142135A1 (ja) |
ZA (1) | ZA201407616B (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017120461A1 (en) | 2016-01-08 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
JP2015515462A (ja) | 2012-03-20 | 2015-05-28 | イェシバ・ユニバーシティYeshiva University | 輸血の有効性を高める方法 |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
EA035336B1 (ru) * | 2013-12-09 | 2020-05-29 | Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити | Способ лечения связанного со старением когнитивного расстройства или заболевания |
EP3218011A4 (en) * | 2014-11-14 | 2018-06-27 | Aima Biotech | Conjugated proteins |
WO2016083331A1 (en) | 2014-11-25 | 2016-06-02 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
EP3096160B1 (en) * | 2015-05-20 | 2020-02-26 | Veoneer Sweden AB | An fmcw vehicle radar system |
NZ738527A (en) | 2015-05-28 | 2022-07-01 | Nanobiotix | Nanoparticles for use as a therapeutic vaccine |
DK3307296T3 (da) | 2015-06-15 | 2021-12-13 | Univ Leland Stanford Junior | Timp2 til anvendelse til behandling af aldringsassocierede tilstande |
US11065277B2 (en) * | 2015-11-09 | 2021-07-20 | Albert Einstein College Of Medicine | Method of ameliorating side effects of sickle cell disease treatments |
WO2017103914A1 (en) * | 2015-12-17 | 2017-06-22 | Regentis Biomaterials Ltd. | Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof |
ES2900302T3 (es) | 2016-04-28 | 2022-03-16 | Alkahest Inc | Fracciones de plasma como terapia para el crecimiento y la progresión del tumor |
EA039316B1 (ru) | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
DK3615057T3 (da) | 2017-04-26 | 2024-01-02 | Alkahest Inc | Doseringsskema til behandling af kognitive svækkelser med blodplasmaprodukter |
US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
CA3070172A1 (en) | 2017-07-18 | 2019-01-24 | VirTech Bio, Inc. | Blood substitutes comprising hemoglobin and methods of making |
BR112021006743A2 (pt) | 2018-10-26 | 2021-07-13 | Alkahest, Inc. | uso de plasma e frações plasmáticas para melhoria de dor, cicatrização de ferida e recuperação pós-operatória |
JP2022129250A (ja) * | 2021-02-24 | 2022-09-05 | 学校法人 中央大学 | ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267269A (en) * | 1980-02-05 | 1981-05-12 | Baxter Travenol Laboratories, Inc. | Red cell storage solution |
JPS56139419A (en) * | 1980-03-31 | 1981-10-30 | Kuraray Co Ltd | Erythrocytic preservative and erythrocytic pharmaceutical for preservation |
EP1032268A4 (en) * | 1997-09-26 | 2003-08-20 | Uab Research Foundation | REDUCED ANTIGENS CELLS AND THEIR USE |
JP2002525334A (ja) * | 1998-09-25 | 2002-08-13 | オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン | N−L−α‐アスパルチル−L−フェニルアラニン1−メチルエステルによる赤血球鎌状化の阻害 |
US6251927B1 (en) * | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
US6875423B1 (en) * | 1999-09-21 | 2005-04-05 | Marcos Intaglietta | Methods for increasing peripheral blood circulation |
EP2292657A1 (en) * | 1999-11-12 | 2011-03-09 | Baxter Biotech Technology S.A.R.L. | Reduced side-effect hemoglobin compositions |
US6811778B2 (en) | 2001-09-10 | 2004-11-02 | Biopure Corporation | Method for improving oxygen transport by stored red blood cells |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
US7144989B2 (en) * | 2002-03-25 | 2006-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof |
US7521174B2 (en) * | 2003-12-05 | 2009-04-21 | Albert Einstein College Of Medicine Of Yeshiva University | Universal red blood cells, methods of preparing same, and uses thereof |
AU2005311251A1 (en) * | 2004-12-01 | 2006-06-08 | Devgen Nv | 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family |
US8741832B2 (en) | 2005-06-10 | 2014-06-03 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated albumin and uses thereof |
WO2007058678A2 (en) * | 2005-06-10 | 2007-05-24 | Albert Einstein College Of Medicine Of Yeshiva University | Uses of pegylated albumin |
US20100196461A1 (en) * | 2009-01-30 | 2010-08-05 | Simpkins Cuthbert O | Resuscitation fluid |
US8815297B2 (en) * | 2009-03-31 | 2014-08-26 | Duke University | Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL |
TWI626057B (zh) * | 2009-06-09 | 2018-06-11 | 普龍製藥有限責任公司 | 血紅素組成物 |
US20110189166A1 (en) * | 2010-01-29 | 2011-08-04 | John Boucher | Methods of treating hemorheologic abnormalities in mammals |
US20130231287A1 (en) * | 2010-02-25 | 2013-09-05 | Parimala Nacharaju | Pegylated albumin polymers and uses thereof |
JP2015515462A (ja) | 2012-03-20 | 2015-05-28 | イェシバ・ユニバーシティYeshiva University | 輸血の有効性を高める方法 |
EP3218011A4 (en) | 2014-11-14 | 2018-06-27 | Aima Biotech | Conjugated proteins |
-
2013
- 2013-03-12 JP JP2015501731A patent/JP2015515462A/ja active Pending
- 2013-03-12 WO PCT/US2013/030355 patent/WO2013142135A1/en active Application Filing
- 2013-03-12 EP EP13764824.2A patent/EP2827887A4/en not_active Withdrawn
- 2013-03-12 BR BR112014023200A patent/BR112014023200A2/pt not_active IP Right Cessation
- 2013-03-12 MX MX2014011186A patent/MX2014011186A/es unknown
- 2013-03-12 IN IN2089MUN2014 patent/IN2014MN02089A/en unknown
- 2013-03-12 US US13/794,978 patent/US8859499B2/en active Active
-
2014
- 2014-08-07 US US14/454,059 patent/US9498537B2/en active Active
- 2014-09-17 CL CL2014002464A patent/CL2014002464A1/es unknown
- 2014-10-20 ZA ZA2014/07616A patent/ZA201407616B/en unknown
-
2015
- 2015-05-19 HK HK15104771.0A patent/HK1204267A1/xx unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015515462A5 (ja) | ||
Hutchens et al. | Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo | |
JP2011088927A5 (ja) | ||
NZ592837A (en) | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents | |
EA201492021A1 (ru) | Антительный состав | |
JP2013530955A5 (ja) | ||
WO2008064299A3 (en) | Methods of reducing porcine circovirus-associated disease outbreaks | |
WO2010100200A3 (en) | Lyophilised antibody formulation | |
MY197091A (en) | Compositions for treating acid-base disorders | |
JP2012528890A5 (ja) | ||
RU2018123666A (ru) | Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина | |
JP2015535243A5 (ja) | ||
WO2019130061A3 (en) | Retinal pigment epithelium cell compositions | |
JP2017522288A5 (ja) | ||
WO2012012388A3 (en) | Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy | |
CN107137700B (zh) | 一种基于干细胞源外泌体的组合物及其在制备治疗心肌梗死的药物中的应用 | |
JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
JP2017525704A5 (ja) | ||
BR112015022565A2 (pt) | composições e métodos para aumentar o potencial terapêutico das células tronco | |
EP2525819A4 (en) | IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES | |
JP2010531659A5 (ja) | ||
Hagiwara et al. | Filtration leukocytapheresis therapy ameliorates lipopolysaccharide-induced systemic inflammation in a rat model | |
CN104906053B (zh) | 注射用重组人粒细胞刺激因子冻干粉针剂 | |
WO2011066201A3 (en) | Methods and systems for treating and preventing cardiac injury in dystrophic subjects | |
WO2011025220A3 (en) | Liver regeneration accelerator comprising betaine |